UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Faculty Profiles

Kathleen Mulligan, PhD

Professor

Kathleen.Mulligan@ucsf.edu

I study the nutritional and metabolic effects of chronic conditions including HIV infection and its therapies, obesity, fatty liver disease, and type 2 diabetes, with a focus on body composition, glucose and lipid metabolism, endocrine function, and bone metabolism; and a strong emphasis on treatments and mechanisms. My research has ranged from leading intense inpatient metabolic ward studies to chairing multicenter trials through consortia such as the adult and pediatric AIDS Clinical Trials Groups and Adolescent Trials Network.

Awards and Honors

2009   Endocrine Society/Pfizer International Award for Excellence in Published Clinical Research, Endocrine Society, 2009-2010

Recent Articles (10)

Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017 Sep 05.

Jacobson DL, Lindsey JC, Coull BA, Mulligan K, Bhagwat P, Aldrovandi GM. The Association of Fat and Lean Tissue with Whole Body and Spine Bone Mineral Density is Modified by HIV Status and Sex in Children and Youth. Pediatr Infect Dis J. 2017 Aug 16.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017 Jun 19.

Schwarz JM, Noworolski SM, Erkin-Cakmak A, Korn NJ, Wen MJ, Tai VW, Jones GM, Palii SP, Velasco-Alin M, Pan K, Patterson BW, Gugliucci A, Lustig RH, Mulligan K. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017 Jun 01.

Lee AP, Mulligan K, Schambelan M, Murphy EJ, Weiss EJ. Growth hormone receptor antagonism with pegvisomant in insulin resistant non-diabetic men: A phase II pilot study. F1000Res. 2017; 6:614.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2016 Nov 15.

Hosek S, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer K, Anderson P, Kiser J, Rooney J, Wilson CM. An HIV Pre-Exposure Prophylaxis (PrEP) Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2016 Sep 13.

Ruan A, Tobin NH, Mulligan K, Rollie A, Li F, Sleasman J, Aldrovandi GM. Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021. J Acquir Immune Defic Syndr. 2016 Aug 1; 72(4):372-5.

Gugliucci A, Lustig RH, Caccavello R, Erkin-Cakmak A, Noworolski SM, Tai VW, Wen MJ, Mulligan K, Schwarz JM. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome. Atherosclerosis. 2016 Oct; 253:171-177.

Lustig RH, Mulligan K, Noworolski SM, Tai VW, Wen MJ, Erkin-Cakmak A, Gugliucci A, Schwarz JM. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity (Silver Spring). 2016 Feb; 24(2):453-60.

View Full Profile

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.